BioSpace News Archive

DermBiont, a clinical-stage biotechnology company announced today positive results meeting primary and secondary endpoints in a Phase 2 clinical trial with a topical formulation of investigational drug SM-020, a specific and potent AKT inhibitor applied by patients at home to their seborrheic keratoses (SK).

Wiley Increases Quarterly Dividend for the 29th Consecutive Year.

Astrotech Corporation’s (NASDAQ: ASTC) subsidiary, BreathTech Corporation, announced today that it has amended its Joint Development and Option Agreement with Cleveland Clinic to include additional areas of focus.

New analyses of PEDFIC Phase 3 trials show that patients whose pruritus improves on Bylvay ® (odevixibat) also experience improvements in sleep, quality of life, serum bile acids and hepatic parameters.

Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Timolol Maleate Ophthalmic Solution, USP 0.5%, 60 pack of 0.3mL unit dose vials (AT3 rated generic equivalent of Timoptic ® in Ocudose ® ) and has begun commercialization activities.

Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced the publication of its multicenter prostate cancer focal therapy study in The Lancet Oncology journal.

Kynos Therapeutics Ltd (Kynos or the Company), an immune-metabolic company with world-leading expertise in the kynurenine pathway and kynurenine 3-monooxygenase (KMO) biology today announced the appointment of Dr Alison Strutt as Chief Finance Officer (CFO).

Athenex announced that Daniel Lang, M.D., President, Athenex Cell Therapy, will participate in The Next Cells & Mechanisms to Watch in Oncology panel at the Truist Securities Cell Therapy Symposium on Tuesday, June 28, 2022 at 11:30 am Eastern Time in New York, NY.

According to Vision Research Reports, the global Regulatory Affairs market is anticipated to grow at a CAGR of 8.9% during forecast period 2021 to 2030 and expected to hit around US$ 20.5 billion by 2030.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a partnership with Epic, the industry leading healthcare software company, to integrate Myriad’s full line of genetic tests with Epic’s expansive network of 600,000 physicians and more than 250 million patients.